Skip to content

Author

Qiang Huang

We have 2 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Aug 2026

Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study

Adding anti-PD-1 or anti-VEGF therapy to chemotherapy improves survival in patients with advanced gastric cancer, yet outcomes remain poor. This Phase Ib/II trial aimed to evaluate the efficacy and safety of combining sintilimab, the bevacizumab biosimilar IBI305, and CapeOX chemotherapy as a first-line treatment for p...

Mo Cheng, Peng-Fei Zhang, Qian-Cheng Hu et al. · 0 citations
Preprint Jul 2026

Agents Don't Just Agree, They Remember: Benchmarking Persistent Sycophancy in Stateful Personal Agents

The Personal Agent Sycophancy Benchmark (PASB) is introduced, a 1,600-task benchmark that traces whether a conversational claim is accepted, written into durable agent state, and reused in a later neutral query, and shows that agent sycophancy is fundamentally a state-writing governance problem.

Xutao Mao, Liang Zhao, Leyao Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.